Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Late adverse effects and quality of life in survivors of testicular germ cell tumour

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. COVID and CopMich: comparing and contrasting COVID-19 experiences in the USA and Scandinavia

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  2. Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Oxytocin antagonists: the next frontier in PE treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. From separation to collaboration: the future of urology

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  5. Clarifying the link between ibuprofen and hypogonadism

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Long-term neurotoxicity and quality of life in testicular cancer survivors-a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Changes in abdominal subcutaneous adipose tissue phenotype following menopause is associated with increased visceral fat mass

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Small RNAs in Seminal Plasma as Novel Biomarkers for Germ Cell Tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Currently, ~95% of patients with testicular germ cell tumour (TGCT) are cured, resulting in an increasing number of TGCT survivors. Although cured, these men face potential late adverse effects and reduced quality of life. Survivors face a twofold increased risk of second malignant neoplasms after chemotherapy and radiotherapy, with evidence of dose-dependent associations. For survivors managed with surveillance or treated with radiotherapy, the risk of cardiovascular disease (CVD) is comparable to the risk in the general population, whereas treatment with chemotherapy increases the risk of life-threatening CVD, especially during treatment and after 10 years of follow-up. Other adverse effects are organ-related toxicities such as neuropathy and ototoxicity. Pulmonary and renal impairment in patients with TGCT treated with chemotherapy is limited. Survivors of TGCT might experience psychosocial distress including anxiety disorders, fear of cancer recurrence and TGCT-specific issues, such as sexual dysfunction. Late adverse effects can be avoided in most patients with stage I disease if followed on a surveillance programme. However, patients with disseminated disease can experience toxicities associated with radiotherapy and chemotherapy, and/or adverse effects related to surgery for residual disease. The severity of adverse effects increases with dose of both chemotherapy and radiotherapy. This Review discusses the most recent data concerning the late adverse effects of today's standard treatments for TGCT.

OriginalsprogEngelsk
TidsskriftNature reviews. Urology
Vol/bind18
Udgave nummer4
Sider (fra-til)227-245
Antal sider19
ISSN1759-4812
DOI
StatusUdgivet - apr. 2021

Bibliografisk note

Funding Information:
The work of M.C. is supported by the Slovak Research and Development Agency under contract no. APVV-15-0086 and APVV-19-0411.

ID: 64231866